VIVEbiotech is a GMP Contract Development and Manufacturing Organisation (CDMO) specialized in lentiviral vectors.
Before VIVEbiotech was established, its team had already reached some key milestones within the Advanced Therapies field. This allowed VIVEbiotech to become an integral service lentiviral CDMO, and since the beginning it has focused its efforts on offering custom services to international customers.
2015 - Today
Lentisoma technology
acquisition
acquisition
Seal of Excellence
from European Commission
from European Commission
GMP
certification
certification
Working for US
and European customers
and European customers
Doubled
production capacity
Project driven company
Through gene-therapy evolution
- More than 40% PhDs
- Multidisciplinary team: Biologists, Pharmacists, Medical Doctors, etc.
- Very low turn-over rate
- Client-driven approach
- Continuous company growth
- Quality-based partner selection: CleanCells, PlasmidFactory, PALL, Sartorius Stedim, etc.
- Other research partners: Ciemat, Sant Pau, FICYT, etc.
- Seal of Excellence from European Commission
